Anti-CEACAM1 recombinant antibodies for cancer therapy
View Patent ↗Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
1. An isolated CEACAM1-specific recombinant monoclonal antibody or an antigen-binding portion thereof, comprising: at least one light chain component and at least one heavy chain component, wherein said heavy chain component comprises the amino acids of SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30; and said light chain component comprises the amino acids of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31 or SEQ ID NO:32, and wherein said antibody or an antigen-binding portion thereof binds the antigen recognized by the monocloncal antibody 5F4, 34B1, or 26H7.
2. The isolated CEACAM1-specific recombinant monoclonal antibody or an antigen binding portion thereof of claim 1 , wherein the anti-CEACAM1-specific recombinant monoclonal antibody is a humanized antibody or portion thereof.
3. An isolated recombinant antibody or antigen-binding portion thereof comprising: a heavy chain complementarity determining region (CDR) 1 consisting of the amino acid residues of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 13; a heavy chain CDR2 consisting of the amino acid residues of SEQ ID NO:2, SEQ ID NO: 8, or SEQ ID NO: 14; a heavy chain CDR3 consisting of the amino acid residues of SEQ ID NO: 3, or SEQ ID NO: 9, or SEQ ID NO: 15; a light chain CDR1 consisting of the amino acid residues of SEQ ID NO: 4, SEQ ID NO:10, SEQ ID NO:16, or SEQ ID NO:19;
a light chain CDR2 consisting of the amino acid residues of SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:17, or SEQ ID NO:20; and a light chain CDR3 consisting of the amino acid residues SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18, or SEQ ID NO: 21; such that said isolated recombinant antibody or antigen-binding portion thereof binds the antigen recognized by 5F4, 34B1, or 26H7.
4. The isolated CEACAM1-specific recombinant monoclonal antibody or an antigen-binding portion thereof of claim 3 , wherein the antibody portion is a Fab fragment, a Fab′ fragment, a Fd fragment, a Fd′ fragment, a Fv fragment, a dAb fragment, a F(ab′) 2 fragment, a single chain fragment, a diabody, or a linear antibody.
5. The antibody or antigen-binding portion thereof of claim 3 , wherein said antibody is linked to a label.
6. The isolated CEACAM1-specific recombinant monoclonal antibody or an antigen-binding portion thereof of claim 3 , further comprising an agent conjugated to the anti-CEACAM1 recombinant antibody or portion thereof to form an immunoconjugate specific for CEACAM1.
7. The isolated CEACAM1-specific recombinant monoclonal antibody or an antigen-binding portion thereof of claim 6 , wherein the agent conjugated to the antibody or antibody fragment thereof is a chemotherapeutic agent, a toxin, a radioactive isotope, a small molecule, an siRNA, a nanoparticle, or a microbubble.
8. A method of treating pancreatic cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated recombinant antibody or antigen-binding portion thereof comprising: a heavy chain complementarity determining region (CDR) 1 consisting of the amino acid residues of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 13; a heavy chain CDR2 consisting of the amino acid residues of SEQ ID NO:2, SEQ ID NO: 8, or SEQ ID NO: 14; a heavy chain CDR3 consisting of the amino acid residues of SEQ ID NO: 3, or SEQ ID NO: 9, or SEQ ID NO: 15; a light chain CDR1 consisting of the amino acid residues of SEQ ID NO: 4, SEQ ID NO:10, SEQ ID NO:16, or SEQ ID NO:19;
a light chain CDR2 consisting of the amino acid residues of SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:17, or SEQ ID NO:20; and a light chain CDR3 consisting of the amino acid residues SEQ ID NO: 6, SEQ ID NO: 12, SEQ ID NO: 18, or SEQ ID NO: 21; such that said isolated recombinant antibody or antigen-binding portion thereof binds the antigen recognized by 5F4, 34B1, or 26H7.
9. The method of claim 8 , wherein the method further comprises the administration of one or more chemotherapeutic agents, angiogenesis inhibitors, cytotoxic agents, or anti-proliferative agents.